Report documents IL-16 in vitreous of VRL, suggesting its role as a biomarker for immune responses.
This report presents the first documentation of vitreous IL-16 in VRL and suggests that IL-May 16, represent a potential adjunct biomarker in this setting. Co-expression of IL-10 and IL-May 16, reflect a dynamic interaction between lymphoma cells and the TME, contributing to immune modulation and treatment resistance. Longitudinal IL-16 monitoring may provide additional insight into disease activity and therapeutic response; however, this requires validation in larger VRL cohorts, ideally including inflammatory controls.
No takes yet. Share an insight, caveat, or question.
Saturno et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: